Lykos’ MDMA-assisted therapy stumbles at adcomm amid questions about study, safety and abuse
An FDA advisory committee voted against backing Lykos Therapeutics’ MDMA-based therapy for post-traumatic stress disorder, a blow to the biotech company’s efforts to bring the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
